+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments



Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments



Drugs 69(5): 515-533



Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and patient risk factors significantly influence CINV. Serotonin 5-HT(3) receptor antagonists plus dexamethasone have significantly improved the control of acute CINV, but delayed CINV remains a significant clinical problem. Two new agents, palonosetron and aprepitant, have recently been approved for the prevention of both acute and delayed CINV. Palonosetron is a second-generation 5-HT(3) receptor antagonist with a longer half-life and a higher binding affinity than first-generation 5-HT(3) receptor antagonists. Aprepitant is the first agent available in the new drug class of neurokinin-1 (NK-1) receptor antagonists. Casopitant is another NK-1 receptor antagonist, which is under review by the US FDA after recent completion of phase III clinical trials. The introduction of these new agents has generated revised antiemetic guidelines for the prevention of CINV. Future studies may consider the use of palonosetron, aprepitant and casopitant with other antiemetic agents (e.g. olanzapine, gabapentin, cannabinoids) in moderately and highly emetogenic chemotherapy, as well as in the clinical settings of multiple-day chemotherapy and bone marrow transplantation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054961492

Download citation: RISBibTeXText

PMID: 19368415

DOI: 10.2165/00003495-200969050-00002


Related references

Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Annals of Oncology 26(6): 1081-1090, 2015

Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron. Therapeutics and Clinical Risk Management 11: 713-729, 2015

Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer. Journal of ChemoTherapy 21(6): 605-610, 2009

Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting. Clinical Advances in Hematology and Oncology 9(11 Suppl 27): 1-14; Quiz 15-6, 2011

Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials. Clinical Advances in Hematology and Oncology 13(10 Suppl 10): 1-14, 2015

Recent Advances in the Management of Chemotherapy-induced Nausea and Vomiting: A Case Study Compendium. Clinical Advances in Hematology and Oncology 8(5 Suppl 9): 1-16, 2010

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opinion on Drug Metabolism and Toxicology 5(12): 1607-1614, 2009

New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opinion on Drug Metabolism and Toxicology 1(1): 143-149, 2005

Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Current Opinion in Supportive and Palliative Care 10(2): 180-188, 2016

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Therapeutics and Clinical Risk Management 4(2): 501-506, 2008

Recent advances in the non-pharmacological management of postoperative nausea and vomiting. British Journal of Anaesthesia 95(1): 77-81, 2005

A Case of "Total Nausea:" An Interprofessional Approach to the Management of Chemotherapy-Induced Nausea/Vomiting Complicated by Anxiety and Existential Distress. Journal of Pain and Symptom Management 55(1): E3-E5, 2018

Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: review and focus on the Belgian situation. Acta Gastro-Enterologica Belgica 77(2): 240-248, 2014

Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Future Oncology 14(1): 77-92, 2018

Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting. Journal of Advanced Pharmaceutical Technology and Research 3(4): 202-209, 2012